Techniques using nanoparticles to fight COVID-19

The severe acute respiratory syndrome-causing coronavirus is very infectious (SARS-CoV-2). Its potential to spread through asymptomatic carriers has dramatically strained the diagnostic resources that are now available. The COVID-19 vaccine is currently being developed, and there are now no clinically demonstrated therapeutic approaches that block the effects of this virus. Expanding testing capabilities, creating efficient medicines, and creating secure vaccinations that offer long-lasting immunity are all strategies that need to be investigated. Many medical uses, including biosensing, drug administration, antimicrobial therapy, and imaging, utilize nanoparticles (NPs) extensively. SARS-CoV-2 is an enveloped virus with a 60–140 nm diameter and particle-like properties. Because they resemble the virus physically, they may closely imitate it and have a strong interaction with its proteins. Hence, NP-based approaches to combating this pathogen have enormous potential. Nanoparticles for diagnostics: Several methods of viral detection have used NPs. Greater sensitivity for optical biosensing is an advantage of metal NPs and QDs (quantum dots) with unique optical characteristics. MNPs (magnetic nanoparticles) are mostly used in the viral extraction process because of their magnetic characteristics. It is also possible to increase the efficacy of virus detection by using nanohybrid structures, which combine the advantages of each NPs type. The virus that causes COVID, known as SARS-CoV-2, was newly identified, and NP-based virus identification has recently been mentioned as a possible approach to uncovering it. With continuous research and development, NPs will probably be essential in improving the accuracy of identifying other biological infections and coronavirus detection1,2. Nanoparticles for therapeutics: Different NPs can create medications that interfere with SARS-CoV-2's attachment to the ACE2 receptor and obstruct cell entry while generally remaining harmless to host cells. Effective antiviral therapies are essential, especially in the early stages of infection, to halt viral replication for as long as necessary for the immune system to fight the virus, lessen cellular damage brought on by viral invasion, and lessen genetic mutations brought on by the virus's high frequency of replication that could result in therapeutic resistance. As very effective upgrades or replacements to many existing antiviral therapies linked to rising drug resistance, NPs with different structures, conjugations, and compositions have been developed and evaluated in various contexts. These NPs' antiviral efficacy, stability, and biocompatibility have been thoroughly examined in tests against different human-infecting viruses, including SARS-CoV-2-like viruses and other coronavirus family members. Additionally, several NPs have been demonstrated to be efficient against various viruses with minimal cytotoxicity by novel antiviral techniques with adjustable combinations, demonstrating the potential of these NPs as study subjects to treat the COVID-19 pandemic using NP-based antiviral medications3. Nanoparticles as immunogenic agents for vaccines: Important information is required to create COVID-19 vaccines. The following four inferences are possible: (1) It is possible to systematically construct coronavirus-like forms and sizes for template-based and supported virus-like particles (VLPs), self-assembled VLPs, and synthesized VLPs. Although preventing contact with the virus's pathogenic genetic components, these characteristics aid in the induction of potent immune responses. (2) Even when using less of the proteins, repeatedly painting antigens on the surface of NP vaccines may boost immune responses; this influence can be strengthened even more by simulating the loops' natural structure. Coronavirus S protein epitopes have generally been used in vaccine production. However, N protein epitopes can also be used to create broad-spectrum vaccines. (3) NPs give a chance to combine adjuvant and antigen delivery capabilities. (4) Reactions of the immune system to respiratory viruses like SARS-CoV-2 are higher when vaccines are targeted directly at mucosal cells, lymph nodes, and DCs (dendritic cells). The introduction of nanosized particles (40–200 nm) to mucosal and alveolar structures is particularly well suited for replicating natural infection pathways and triggering immediate immune responses in tissues that have been adversely damaged4,5. NPs are therefore anticipated to be essential in the struggle against COVID. Different NPs' optical and magnetic characteristics may be utilized to make diagnostic test kits. Because of the strong structural and physicochemical similarities between synthetic NPs and SARS-CoV-2, NPs are useful for intervention. NPs offer the possibility of producing vaccines quickly and securely using component proteins rather than entire viruses. In addition, broad-spectrum respiratory drugs and vaccinations that may protect us from infectious viruses and prepare us for potential pandemics may be developed using NPs6. Ethical approval None. Consent Not found in this study. Source of funding There are no funding sources for this research. Author contribution S.Z.: conceptualization, data curation, writing – original draft preparation, and writing – reviewing and editing; A.B.A.: writing – reviewing and editing, visualization, and supervision; H.H. and A.A.A.: data curation, writing – original draft preparation, and writing – reviewing and editing. Conflicts of interest disclosure The authors declare no conflicts of interest. Research registration unique identifying number (UIN) Not applicable. Guarantor Ali Alnazza Alhamad. Provenance and peer review No invitation to paper. Data availability statement Data sharing is not applicable to this article.